| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross Margin | 20.40% | 22.98% | — | — | — |
| Operating Margin | -631.01% | -99.84% | — | — | — |
| EBITDA Margin | -630.76% | -99.67% | — | — | — |
| Net Margin | -931.19% | -68.29% | — | — | — |
| Current Ratio | 0.16 | 0.07 | 0.01 | 0.10 | 0.01 |
| Quick Ratio | 0.15 | -0.07 | 0.01 | 0.10 | 0.01 |
| Debt / Equity | 0.02 | 0.02 | 0.01 | -30.36 | — |
| ROE | -21.30% | -1.68% | 0.26% | 94.35% | 156.04% |
| ROA | -15.80% | -104.68% | 1.10% | -2.89% | -0.47% |
| Asset Turnover | 0.02 | 1.53 | — | — | — |
| Book Value / Share | 5.63 | 31.95 | 19.88 | -0.03 | — |
OSR Holdings Inc. is a healthcare holding company operating a hub-and-spoke model with wholly owned subsidiaries focused on advancing biomedical innovations across immuno-oncology, regenerative biologics, noninvasive glucose monitoring, and medical device distribution. Through subsidiaries like Vaximm AG, it develops oral T-cell immunotherapies targeting tumor vasculature, including candidates such as VXM01 for glioblastoma in phase 2 trials, and preclinical products addressing mesothelin, WT1, CEA, and PD-L1. In regenerative biologics, it advances design-augmented assets like DRT-102 for spinal fusion and DRT-101 for osteoarthritis. Woori IO Co., Ltd. pioneers needle-free glucose monitoring using near-infrared spectroscopy technology, while another segment distributes neurovascular intervention systems in South Korea. Headquartered in Bellevue, Washington, with operations in the United States, Switzerland, and South Korea, OSR Holdings Inc. centralizes expertise to support its portfolio, emphasizing simplification through innovation to develop differentiated treatments for cancer, degenerative diseases, diabetes management, and neurovascular conditions.